1. Home
  2. RNXT vs GDTC Comparison

RNXT vs GDTC Comparison

Compare RNXT & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNXT
  • GDTC
  • Stock Information
  • Founded
  • RNXT 2012
  • GDTC 2018
  • Country
  • RNXT United States
  • GDTC Singapore
  • Employees
  • RNXT N/A
  • GDTC N/A
  • Industry
  • RNXT Biotechnology: Pharmaceutical Preparations
  • GDTC Biotechnology: Pharmaceutical Preparations
  • Sector
  • RNXT Health Care
  • GDTC Health Care
  • Exchange
  • RNXT Nasdaq
  • GDTC Nasdaq
  • Market Cap
  • RNXT 31.6M
  • GDTC 29.4M
  • IPO Year
  • RNXT 2021
  • GDTC 2023
  • Fundamental
  • Price
  • RNXT $1.16
  • GDTC $2.65
  • Analyst Decision
  • RNXT Strong Buy
  • GDTC Buy
  • Analyst Count
  • RNXT 1
  • GDTC 1
  • Target Price
  • RNXT $9.00
  • GDTC $5.00
  • AVG Volume (30 Days)
  • RNXT 203.6K
  • GDTC 25.0K
  • Earning Date
  • RNXT 03-31-2025
  • GDTC 01-01-0001
  • Dividend Yield
  • RNXT N/A
  • GDTC N/A
  • EPS Growth
  • RNXT N/A
  • GDTC N/A
  • EPS
  • RNXT N/A
  • GDTC N/A
  • Revenue
  • RNXT N/A
  • GDTC $330,254.00
  • Revenue This Year
  • RNXT N/A
  • GDTC $14.71
  • Revenue Next Year
  • RNXT N/A
  • GDTC N/A
  • P/E Ratio
  • RNXT N/A
  • GDTC N/A
  • Revenue Growth
  • RNXT N/A
  • GDTC N/A
  • 52 Week Low
  • RNXT $0.77
  • GDTC $1.20
  • 52 Week High
  • RNXT $1.86
  • GDTC $4.05
  • Technical
  • Relative Strength Index (RSI)
  • RNXT 38.10
  • GDTC 49.22
  • Support Level
  • RNXT $1.32
  • GDTC $2.55
  • Resistance Level
  • RNXT $1.40
  • GDTC $2.94
  • Average True Range (ATR)
  • RNXT 0.09
  • GDTC 0.22
  • MACD
  • RNXT -0.03
  • GDTC 0.01
  • Stochastic Oscillator
  • RNXT 17.07
  • GDTC 53.23

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: